ANDOVER, Mass., Nov. 6, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2023.
Recent Highlights
- Net revenue of $66.4 million in the third quarter of 2023, a 159% increase compared to the third quarter of 2022, including $1.6 million non-recurring charter revenue
- Closed acquisition of Summit Aviation, enabling the addition of aviation service to NOP offering, driving $2.1 million incremental transplant related revenue in the third quarter
“The third quarter was a critical execution period for TMDX as we integrated a new business, expanded our NOP clinical support capacity, and launched a first-of-its kind business to expand our NOP product and service offering,” said Waleed Hassanein, MD, President and Chief Executive Officer. “We are pleased with our third quarter performance and we firmly believe that we are building a great foundation for further acceleration of our growth in 2024 and beyond.”
Third Quarter 2023 Financial Results
Total revenue for the third quarter of 2023 was $66.4 million, a 159% increase compared to $25.7 million in the third quarter of 2022. The increase was due primarily to greater utilization of the company’s NOP across all three OCS products as well as the addition of logistics and aviation revenue. Revenue from the new, transplant related aviation and logistics offerings was $2.1 million. Additionally, total revenue includes $1.6 million in non-recurring revenue attributable to Summit Aviation’s charter business that TransMedics intends to exit in early 2024.
Gross margin for the third quarter of 2023 was 61%, compared to 71% in the third quarter of 2022, and compared to 70% in the second quarter of 2023. Gross margin for the third quarter was unfavorably impacted by transition initiatives following the Summit Aviation acquisition, and the expected inefficiencies inherent in the transition out of its legacy charter business and the launch of the new transplant aviation business. Total cost of revenue $2.3 million of non-transplant related costs that reduced gross margin by 200 basis points.
Operating expenses for the third quarter of 2023 were $69.0 million, compared to $23.7 million in the third quarter of 2022, and compared to $37.6 million in the second quarter of 2023. The increase in operating expense was driven primarily by an acquired in-process research and development charge of $27.2 million and an additional $2.0 million in non-recurring acquisition-related costs. In addition, TransMedics continued investing in personnel, NOP support, and the development of the company’s digital platform and next generation OCS. Third quarter operating expenses in 2023 also included $5.1 million of stock compensation expense compared to $2.7 million of stock compensation expense in the third quarter of 2022, and $4.9 million of stock compensation in the second quarter of 2023.
Net loss for the third quarter of 2023 was $25.4 million, compared to $7.4 million in the third quarter of 2022. The increase in net loss was driven primarily by $29.2 million in non-recurring acquisition-related costs.
Cash was $427.1 million as of September 30, 2023.
2023 Financial Outlook
TransMedics is updating its full year 2023 revenue guidance to be in the range of $222 million to $230 million, which represents 138% to 146% growth compared to the company’s prior year revenue. TransMedics’ prior 2023 revenue guidance was $180 million to $190 million.
Webcast and Conference Call Details
The TransMedics management team will host a conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT on Monday, November 6, 2023. A live and archived webcast of the event will be available on the “Investors” section of the TransMedics website at www.transmedics.com.
About TransMedics Group, Inc.
TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Forward-Looking Statements
This press release contains forward-looking statements with respect to, among other things, our full-year guidance, and statements about our operations, financial position, and business plans, including our plans to expand our NOP offering, increase revenue opportunities, and exit Summit Aviation’s charter business. These forward-looking statements are subject to a number of risks and uncertainties. Our Management cannot predict all risks, nor can we assess the impact of all factors on the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: that we continue to incur losses; our ability to attract and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the OCS; our ability to expand access to OCS through the NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private payors of benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our net revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States and the European Union; our ability to adequately respond to FDA follow-up inquiries in a timely manner; performance of our third-party suppliers and manufacturers; our dependence on third parties to transport donor organs and medical personnel for our NOP; price increases of the components of our products; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products that are or may become available; the impact of any product recalls or improper use of our products; risks related to retaining key Summit employees and risks related to providing aviation services and owning aircraft; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the “SEC”). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Investor Contact:
Brian Johnston
332-895-3222
Investors@transmedics.com
|
TransMedics Group, Inc. |
||||||||
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||
|
2023 |
2022 |
2023 |
2022 |
|||||
|
Revenue: |
||||||||
|
Net product revenue |
$ 47,740 |
$ 21,299 |
$ 124,195 |
$ 54,160 |
||||
|
Service revenue |
18,690 |
4,384 |
36,254 |
7,924 |
||||
|
Total revenue |
66,430 |
25,683 |
160,449 |
62,084 |
||||
|
Cost of revenue: |
||||||||
|
Cost of net product revenue |
11,086 |
4,231 |
26,950 |
11,689 |
||||
|
Cost of service revenue |
14,682 |
3,337 |
27,330 |
5,826 |
||||
|
Total cost of revenue |
25,768 |
7,568 |
54,280 |
17,515 |
||||
|
Gross profit |
40,662 |
18,115 |
106,169 |
44,569 |
||||
|
Gross Margin |
61 % |
71 % |
66 % |
72 % |
||||
|
Operating expenses: |
||||||||
|
Research, development and clinical trials |
11,132 |
6,808 |
25,294 |
21,056 |
||||
|
Acquired in-process research and development expenses |
27,212 |
— |
27,212 |
— |
||||
|
Selling, general and administrative |
30,653 |
16,851 |
84,993 |
48,171 |
||||
|
Total operating expenses |
68,997 |
23,659 |
137,499 |
69,227 |
||||
|
Loss from operations |
(28,335) |
(5,544) |
(31,330) |
(24,658) |
||||
|
Other income (expense): |
||||||||
|
Interest expense |
(3,590) |
(787) |
(7,186) |
(2,719) |
||||
|
Other income (expense), net |
4,996 |
(1,076) |
7,982 |
(2,087) |
||||
|
Total other income (expense), net |
1,406 |
(1,863) |
796 |
(4,806) |
||||
|
Loss before income taxes |
(26,929) |
(7,407) |
(30,534) |
(29,464) |
||||
|
(Provision) benefit for income taxes |
1,507 |
(19) |
1,475 |
(47) |
||||
|
Net loss |
$ (25,422) |
$ (7,426) |
$ (29,059) |
$ (29,511) |
||||
|
Net loss per share attributable to common |
$ (0.78) |
$ (0.25) |
$ (0.89) |
$ (1.03) |
||||
|
Weighted average common shares outstanding, |
32,614,059 |
30,229,936 |
32,474,522 |
28,729,649 |
||||
|
TransMedics Group, Inc. |
||||
|
September 30, 2023 |
December 31, 2022 |
|||
|
Assets |
||||
|
Current assets: |
||||
|
Cash |
$ 427,110 |
$ 201,182 |
||
|
Accounts receivable |
60,654 |
27,611 |
||
|
Inventory |
39,365 |
20,605 |
||
|
Prepaid expenses and other current assets |
9,595 |
2,896 |
||
|
Total current assets |
536,724 |
252,294 |
||
|
Property, plant and equipment, net |
131,004 |
19,223 |
||
|
Operating lease right-of-use assets |
6,861 |
5,130 |
||
|
Restricted cash |
500 |
500 |
||
|
Goodwill |
11,673 |
— |
||
|
Acquired intangible assets, net |
2,405 |
— |
||
|
Other non-current assets |
60 |
— |
||
|
Total assets |
$ 689,227 |
$ 277,147 |
||
|
Liabilities and Stockholders’ Equity |
||||
|
Current liabilities: |
||||
|
Accounts payable |
$ 12,836 |
$ 3,341 |
||
|
Accrued expenses and other current liabilities |
31,651 |
18,635 |
||
|
Deferred revenue |
2,629 |
241 |
||
|
Operating lease liabilities |
1,985 |
1,444 |
||
|
Total current liabilities |
49,101 |
23,661 |
||
|
Convertible senior notes, net |
446,448 |
— |
||
|
Long-term debt, net |
58,986 |
58,696 |
||
|
Operating lease liabilities, net of current portion |
8,232 |
7,415 |
||
|
Total liabilities |
562,767 |
89,772 |
||
|
Total stockholders’ equity |
126,460 |
187,375 |
||
|
Total liabilities and stockholders’ equity |
$ 689,227 |
$ 277,147 |
||
View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-third-quarter-2023-financial-results-301979063.html
SOURCE TransMedics Group, Inc.
